In a recent briefing at the Senate Health Committee, Trump & World Health Organization (WHO) officials are ready to partner up and provide investment funding to pharmaceutical companies who are able to massively produce coronavirus vaccines for the people of the United States.
WHO estimates that each month 89 million medical masks, 76 million examination gloves and 1.6 million goggles will be required for COVID-19. The World Health Organization is also working with governments & manufacturers to ramp up production of medical and PPE supplies.
With surgical masks having increased six-fold, N95 respirators have more than tripled and gowns twice as much as a part of this outbreak U.S. Military has recently announced that they’re working on developing coronavirus vaccine.
Companies that are a great fit for WHO & Trump Officials:
Heat Biologics (HTBX)
- On 3/2/20 Heat Biologics, Inc. filed a provisional patent application that applies its immune system activating technology for treating or preventing infection with the SARS-CoV-2 virus that causes coronavirus disease 2019 (COVID-19).
2. Pipeline is focused on T-cell activation and co-stimulation, as well as dual-acting immunotherapies to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologics.
iBio (IBIO)
Originally built in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense
- iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic.
FastPharmingTM optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for an active pharmaceutical ingredient (API). iBio’s process development team is integrated with its manufacturing team to optimize processes and technology transfer.
On 2/3/20 iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine, Collaboration with Beijing CC-Pharming’s research will deliver product candidates which can then be quickly produced at iBio’s FastPharming Manufacturing Facility.
Beijing CC-Pharming Ltd. Dr. Kevin Wang (Chairman and Chief Scientific Officer, CC-Pharming), “This is an important collaboration to develop plant-derived vaccine strategies for the emerging coronavirus outbreak here in China, and around the world. iBio’s capabilities will enhance our ability to rapidly scale-up vaccine candidate production in effort to combat the 2019-nCoV virus’ threat to global health.”
4/15/19 | iBio press briefing with CC Pharming
Inovio Pharmaceutical (INO)
1/30/20 | Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
Inovio recently announced that it is developing INO-4800 through Phase 1 human testing in the U.S. to evaluate safety and immunogenicity with the support of an initial grant up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
The goal of this collaboration is to leverage Advaccine’s expertise to run a Phase 1 trial in China in parallel with Inovio’s clinical development efforts in the U.S. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800. The collaboration allows us to enter China and deliver our vaccine into the areas where they need it most as soon as possible. Our shared goal is to utilize both company’s expertise in developing vaccines for emerging infectious diseases and hopefully achieve an accelerated regulatory approval for INO-4800.”
Inovio’s participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop vaccines against emerging viruses with pandemic potential, proven vaccine development capabilities, and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase 2 trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Those efforts are supported by CEPI funding and partnership.
In a recently published paper in Lancet Infectious Diseases, Inovio’s Phase 1 study of INO-4700, its MERS-CoV vaccine, demonstrated it was well-tolerated and furthermore induced high levels of antibody responses in approximately 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.
Tonix Pharmaceuticals (TNXP)
On 2/26/20 Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus
Tonix is developing TNX-801 (live horsepox virus vaccine for percutaneous administration) as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a monkeypox preventing vaccine. The Company believes that its proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents.
Under the terms of the research collaboration, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from the virus that causes COVID-19. Horsepox is closely related to vaccinia vaccines, which are a group of orthopoxviruses that have been used as smallpox vaccines.
- 2/02/17 | Tonix Pharmaceuticals Has Previous Experience Working in Viral Biodefense
- https://www.tonixpharma.com/news-events/press-releases/detail/1052/tonix-pharmaceuticals-announces-demonstrated-vaccine
- Small Pox: TNX-801, is a live form of horsepox virus (HPXV) that has been demonstrated to have protective vaccine activity in mice.
Guardion Health Sciences (GHSI)
On 2/26/20 Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
Guardion has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.The formula will be a unique and exclusive brand of HWGB.
The formula is designed to provide both immuno-supportive and anti-inflammatory benefits to its users. The formula has not been used nor tested, nor is it intended to specifically address symptoms of the current COVID-19 virus.
